ID
13750
Beskrivning
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure; ODM derived from: https://clinicaltrials.gov/show/NCT01133886
Länk
https://clinicaltrials.gov/show/NCT01133886
Nyckelord
Versioner (1)
- 2016-03-02 2016-03-02 -
Rättsinnehavare
CC BY-NC 3.0
Uppladdad den
2 mars 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Acute Myeloid Leukemia NCT01133886
Eligibility Acute Myeloid Leukemia NCT01133886
- StudyEvent: Eligibility
Beskrivning
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beskrivning
1. nursing and pregnant females.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Beskrivning
2. females of childbearing potential and males not willing to practice an effective method of contraception whilst receiving decitabine and for 2 months after the last infusion.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C3831118
- UMLS CUI [2]
- C0700589
Beskrivning
3. patients with previous malignancy or concurrent malignancy.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0006826
Beskrivning
4. uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure and unstable angina pectoris.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0009488
Beskrivning
5. ongoing oral corticosteroids are not permitted. however, use of corticosteroids (topical and inhaled) is permitted and prophylactic steroids are allowed for transfusion reactions.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0001617
Beskrivning
6. patients who have received any investigational agent within the 30 days preceding the first dose of study drug.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1875319
Beskrivning
7. patients who have received prior intensive combination chemotherapy or high-dose cytarabine (>/= 1g/m*2 per dose). (prior biologic therapies, targeted therapies and single agent chemotherapy are allowed).
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0010711
Beskrivning
8. patients who have an active viral or bacterial infection. note: no patient is allowed to enter the study unless infections have been fully treated and the patient has remained afebrile for 7 days without antibiotics.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0009450
Beskrivning
9. patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0002880
- UMLS CUI [2]
- C0272286
Beskrivning
10. patients who have previously been treated with decitabine.
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C0049065
- UMLS CUI [1,2]
- C1514463
Beskrivning
11. patients who have known positive serology for hiv.
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0019682
Beskrivning
12. patients with a condition that may be unable to comply with the treatment and monitoring requirements of the study.
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Similar models
Eligibility Acute Myeloid Leukemia NCT01133886
- StudyEvent: Eligibility
C0023480 (UMLS CUI [2])
C0023467 (UMLS CUI [3])
C1982687 (UMLS CUI [4])
C0438286 (UMLS CUI [1,2])
C0201899 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
C0010711 (UMLS CUI [2])
C0272286 (UMLS CUI [2])
C1514463 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])